Eating fruit, such as pomegranates, that contain anti-aromatase phytochemicals reduces the incidence of hormone-dependent breast cancer, according to results of a study published in the January issue of Cancer Prevention Research , a journal of the American Association for Cancer Research. Pomegranate is enriched in a series of compounds known as ellagitannins that, as shown in this study, appear to be responsible for the anti-proliferative effect of the pomegranate. Previous research has shown that pomegranate juice -- punica granatum L -- is high in antioxidant activity, which is generally attributed to the fruit's high polyphenol content. Ellagic acid found in pomegranates inhibits aromatase, an enzyme that converts androgen to estrogen. Aromatase plays a key role in breast carcinogenesis; therefore, the growth of breast cancer is inhibited.
If your cancer comes back after treatment | Breast cancer | Cancer Research UK
Introduction: Reoperative sentinel lymph node biopsy SLNB is feasible in patients with local recurrence LR of invasive breast cancer but it remains unclear if this procedure affects either treatment or outcome. In this study, we ask whether axillary restaging vs. Methods: We queried our institutional database to identify patients treated surgically for invasive breast cancer with a negative SLNB who developed ipsilateral breast or chest wall recurrence as a first event. We excluded those with gross nodal disease at the time of LR.
Study Confirms Letrozole Prevents More Breast Cancer Recurrences than Tamoxifen
After a median of 8 years of follow-up from a large randomized trial, women with estrogen receptor positive breast cancer who received 5 years of treatment with the aromatase inhibitor letrozole were less likely to have their cancer recur or to die during follow-up than women who had 5 years of treatment with tamoxifen. In addition, 5 years of sequential treatment—either 2 years of letrozole followed by 3 years of tamoxifen or 2 years of tamoxifen followed by 3 years of letrozole—was not better than 5 years of letrozole alone at preventing recurrence or death. Researchers from 27 countries enrolled 8, postmenopausal women with invasive breast cancer that could be removed surgically in the trial. After surgery, the women were randomly assigned to one of four groups: 5 years of letrozole letrozole monotherapy , 5 years of tamoxifen tamoxifen monotherapy , or one of the two sequential treatment groups.
For some women, breast cancer may come back after treatment — sometimes years later. This is called a recurrence. Recurrence can be local in the same breast or in the surgery scar , regional in nearby lymph nodes , or in a distant area. Cancer that is found in the opposite breast without any cancer elsewhere in the body is not a recurrence—it is a new cancer that requires its own treatment.